Tag Archives: finance

Hot Investor Mandate: Subsidiary of China-Based Enterprise Partners With and Invests in Clinical-Stage Biotech and R&D Enabling Technologies, Investing Up to $100M

1 Jul

A U.S. subsidiary of a China-headquartered enterprise focused on advanced manufacturing and technical services, medical and healthcare, trade, and engineering services. The firm is seeking investment opportunities in life sciences and healthcare. The firm is open to various deal structures, including equity investments, M&A, and joint ventures. 
 

For equity investments, the firm’s sweet spots are Series A and Series B, although the firm is capable of making later-stage investments. Typical check sizes range from $10M to $100M. While primarily focused on opportunities in the U.S., the firm is also open to investments in North and South America. 
 
The firm is most interested in biotech therapeutics and pharmaceuticals and remains opportunistic regarding modalities and indications. The firm typically evaluates assets in Phase I or Phase II. Other areas of interest include hospital products, especially those leveraging AI, as well as surgical tools and R&D research technologies. 
 
The firm does not have specific requirements for a company’s founding team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com

Hot Investor Mandate: Private Investment Firm Seeks Seed-Stage Investment Opportunities in Medical Devices and Digital Health Across the Globe

1 Jul

A privately funded investment firm based in Canada is focused on making direct investments in the following business sectors: medical technology, medical clinics, healthcare IT and healthcare real estate.  In medtech, the firm seeks to invest in seed stage companies.  The firm looks to partner and fund scientific founders to launch a new company and will primarily invest in the seed stage round. The firm typically allocates $100K-$200K, and will syndicate with other investors outside of their region to invest in larger rounds of $500K or more. The firm has physician, medical experience, particularly in the surgical field. The firm invests globally and is currently seeking new investment opportunities. 
 
In the life sciences, the firm is currently seeking to invest in medical devices and healthcare IT. The firm is opportunistic in terms of the class of device and indications, and has particular interest in surgical devices and tools. The firm is additionally interested in digital health, especially those with a software component. The firm prefers to invest in the pre-prototype stage and with particular preference to very early-stage preclinical technology. 
 
The firm is seeking startups with a maximum $5M pre-money valuation and will invest in pre-revenue companies. The firm is very hands-on after an investment, opening up and bringing their network to their portfolio companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com

Hot Investor Mandate: Venture Arm of Foundation Invests in Seed to Series A Life Science Technologies that Address Brain Cancer and Adjacent CNS Diseases

1 Jul

A private family foundation dedicated to advancing brain tumor research employs a venture philanthropy investment model, which combines deep disease-focused expertise with funding for high-risk/high-reward opportunities. The foundation’s fund typically participates in seed to series A financing rounds with initial investment ranging from $250K to $1M and potential for follow-on investments. The fund is looking to make 3-5 investments per year, primarily within the US and Canada. As a subsidiary of the foundation, the fund will leverage the extensive network and expertise of the foundation and is active in supporting their portfolio companies. The fund does not typically lead rounds and more often co-invests. 
 
The fund focuses on primarily on brain tumor and will consider all technology types, including therapeutics, medical devices, and diagnostics. The fund will also consider adjacent spaces such as neuroscience, as long as there are potential implementations in brain cancer. The fund is also open to talking with companies that do not have a pipeline in brain cancer currently but have potential application in brain cancer in the future. The fund seeks to make investments that are impactful for the company, and typically prefers companies in pre-clinical or early clinical stages, especially for therapeutics. For diagnostics, the fund may consider assets that are in later stages of clinical development. 
 
An ideal founding team will have complementary skill sets, and expertise on the business or the fundraising front is a plus. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com

Hot Investor Mandate: Pre-Seed and Seed Stage Focused Fund Seeks USA-Based Medical Device and Digital Health Technologies in Cardiology, Women’s Health, and More

1 Jul

A US-based venture fund invests only in seed and pre-seed rounds, and focuses solely on opportunities in healthcare IT, medtech and consumer health. The firm primarily invests in U.S. based companies but can invest in any geography. 
 
The firm invests in very early stage companies across the healthcare innovation ecosystem, including healthcare IT, medical devices, and consumer health. The firm is highly interested in preventative healthcare, future of work and healthcare IT applications. The firm is open to investing in any area of medicine, but has specific interest in opportunities in cardiology, pulmonary diseases, diabetes, and women’s health. 
 
The firm does not invest in companies that have already raised over $5 million in dilutive capital. The firm seeks to invest in high quality management teams, and prefers to work with experienced entrepreneurs that have a proven track record in their sector. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com

Investor Panels at RESI Boston September

24 Jun

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

RESI Boston returns on September 17, 2025 at the Westin Copley Place, once again serving as a core event during Biotech Week Boston. Organized by Life Science Nation, RESI (Redefining Every Stage of Investment) brings together life science and healthcare companies with hundreds of investors and strategic partners for a day of partnering, networking, educational content, and exhibits.

A highlight of every RESI conference is the investor panel programming, where active investors and strategics speak directly to entrepreneurs about what they’re looking for, how they invest, and how startups can position themselves for success. The upcoming September event will feature deep dives into some of the most dynamic areas of healthcare innovation, featuring speakers from impact investors, corporate venture arms, Big Pharma, family offices, and more.

Impact Investors & Venture Philanthropy Panel

The Role of Impact Investing in the Healthcare Ecosystem

Impact investors and venture philanthropists are playing a growing role in backing early-stage healthcare ventures, especially those addressing health equity and underserved areas. In this panel, leaders in the field will discuss how they define and measure impact, what they look for in mission-driven ventures, and how they work with founders to align values with milestone-based progress. Attendees will gain insight into how this capital is deployed to catalyze innovations that go beyond traditional ROI.


Mental & Behavioral Health Panel

Investing in Solutions for Higher Quality of Life and Wellbeing

With 1 in 8 people globally affected by mental disorders, demand for novel solutions in behavioral health continues to grow. This panel features investors who are actively backing companies developing digital tools, neurotechnologies, care delivery innovations, and novel therapeutics. Panelists will explore challenges such as stigma, reimbursement, and regulation—along with what it takes for startups to stand out in this vital and rapidly evolving market.


Oncology Innovation Panel

Latest Scientific Breakthroughs and Future Outlook

Oncology continues to attract robust investor interest, yet the bar for scientific rigor and differentiation is high. This session gathers investors focused on oncology diagnostics, therapeutics, and platforms to discuss what excites them in the current landscape and what it takes to succeed. Topics include scientific novelty, clinical de-risking, commercial potential, and where the next wave of oncology innovation may arise.


Corporate VC Panel

Venture and Innovation Arms Making Strategic Investments

Corporate VCs offer much more than capital, they bring strategic alignment, deep expertise, and long-term partnership opportunities. In this session, leaders from CVC arms of major pharma, biotech, and medtech companies will discuss how they source and evaluate early-stage deals, what startups should expect post-investment, and how founders can navigate alignment with a corporate parent. This panel is essential for startups seeking strategic investors.


Diagnostics Panel

Investing in Innovations for Preventative and Personalized Care

As diagnostics become increasingly central to precision medicine and population health, investors are paying close attention. Panelists in this session will discuss how they evaluate new diagnostic technologies, from regulatory and reimbursement outlooks to commercial differentiation and unmet need. For entrepreneurs developing platforms in oncology, infectious disease, or chronic conditions, this discussion will provide actionable guidance on positioning and funding strategies.


Partnering with Big Pharma Panel

What Startups Need to Know to Get on Big Pharma’s Radar

Securing a partnership with Big Pharma can be a transformative milestone. This panel features business development and venture leaders from leading pharmaceutical companies who will share what they look for in early-stage collaborations. Learn how they assess risk, stage readiness, and strategic fit—plus how startups can build compelling cases for co-development, licensing, or investment.


Family Offices Panel

Perspectives on Early-Stage Investments

Family offices have become increasingly visible in early-stage healthcare deals, often offering patient capital and values-driven investment strategies. This panel will unpack how these investors approach opportunity evaluation, what sets them apart from traditional VCs, and how they support portfolio companies beyond capital. Attendees will also hear practical advice for engaging family offices and building meaningful relationships.


Whether you’re developing breakthrough diagnostics, therapeutics, platforms, or care delivery solutions, the RESI Boston investor panels offer a unique opportunity to hear directly from the funders shaping the future of healthcare.

Interested in sharing your insights at RESI? Reach out to join our speaker lineup!

Register by July 11 to lock in Super Early Bird Rates and save $300. Secure your spot today and join 400+ investors and strategic partners this September in Boston.

Introducing the Investor Judges for the Innovator’s Pitch Challenge at RESI Boston 

10 Jun

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

RESI Boston takes place on June 16, and Life Science Nation is pleased to announce the investor judges participating in this event’s Innovator’s Pitch Challenge (IPC). With more than 50 companies presenting across 14 sessions, the IPC offers life science startups a high-impact opportunity to gain visibility, pitch directly to active investors, and receive valuable feedback in real time.

Each session will feature investor and strategic partner judges with expertise spanning therapeutics, medical devices, diagnostics, digital health, and life science tools. Following every pitch, judges will lead a live Q&A to assess the opportunity and share insights from the investor perspective.

Every IPC company will also have a dedicated table in the RESI Exhibition Hall, making it easy for attendees to connect with founders and learn more.

All registered attendees will be invited to vote online for their favorite companies, and the Top 3 companies will be announced at the end of the day’s cocktail reception. Winners will receive a prize and be featured in an upcoming issue of the LSN newsletter.

Scroll down to see which investors will serve as judges for this year’s IPC:

John Abeles
John Abeles
General Partner
Northlea Partners
Chris Aleong
Chris Aleong
VP
BioIdeations
Christina Ansted
Christina Ansted
Sr. Managing Partner
RCP Venture Capital
Jit Basak
Jit Basak
Investor
Launchit Ventures
Jay Batchu
Jay Batchu
Entrepreneur in Residence
Xontogeny
Randy Berholtz
Randy Berholtz
Sr. Advisor
Mesa Verde Venture Partners
Jeff Berman
Jeff Berman
Managing Partner & Co-Founder
Big Tree Innovation Fund
Kalyan Chakravarthy
Kalyan Chakravarthy
Sr. Manager, External Innovation
Ipsen S.A.
Jo Chaturvedi-Durant
Jo Chaturvedi-Durant
Sr. Investor & Venture Partner
VU Venture Partners
Shailesh Chavan
Shailesh Chavan
Managing Partner
Transatlantic Life Science Venture
Nicolas Cindric
Nicolas Cindric
Partner
Yahara Ventures
Javier Coindreau
Javier Coindreau
General Partner (Boston)
Sila B Health Ventures
Bettina Ernst
Bettina Ernst
Director
BERNINA BioInvest
Alex Fair
Alex Fair
Managing Partner
Medstartr Capital
Dimitra Georganopoulou
Dimitra Georganopoulou
Managing Director
Qral Ventures
Serban Georgescu
Serban Georgescu
Due Diligence Chair
Mass Medical Angels
Ken Grise
Ken Grise
Principal
Sixty Degree Capital
Marco Gulla
Marco Gulla
Investment Associate
Health Technology Holding (HTH)
George Hong
George Hong
Investor
H Advisor Group
Guanghui Hu
Guanghui Hu
Venture Partner & CEO
Viva BioInnovator
Kristin King-Jankiewicz
Kristin King-Jankiewicz
Member & Head of Group Management
Boston Harbor Angels
Claire Leurent
Claire Leurent
Managing Director
AbbVie
Vivian Li
Vivian Li
SA
K2 Venture Partners
Ali Malihi
Ali Malihi
President
Back Bay Group
Nune Martiros
Nune Martiros
Sr. Associate
Paladin Capital Group
Jim McGough
Jim McGough
Managing Partner
Mid Atlantic Bio Angels
Ralph Morales III
Ralph Morales III
Venture Partner / Executive-in-Residence
Aquillius Ventures
Jose Navarro
Jose Navarro
Scientific Director & Partner
quadraScope Venture Fund
Lizzie Ngo
Lizzie Ngo
Principal
Longwood Fund
Yoichi Omae
Yoichi Omae
BD Director
Asahi Intecc USA Inc
Soyoung Park
Soyoung Park
General Partner
1004 Venture Partners
Chandra Ramanathan
Chandra Ramanathan
VP and Head of External Innovation, Life Sciences Innovation Group
Danaher Corporation
Nans Rivat
Nans Rivat
VP
PACE Healthcare Capital
Shreya Sawant
Shreya Sawant
Venture Partner
Aquillius Ventures
Pranav Seshadri
Pranav Seshadri
Investor
T.Rx Capital
Jason Shieh
Jason Shieh
Partner/Co-Founder
HelixPoint Capital
Oliver Sims
Oliver Sims
Investment Manager
Octopus Ventures
Alex Spicer
Alex Spicer
M&A Associate
SERB Pharmaceuticals
Sri Sriadibhatla
Sri Sriadibhatla
Director, Healthcare Investment Group
Ben Franklin Technology Partners of Southern Pennsylvania
Isaac Stoner
Isaac Stoner
EIR
Slater Technology Fund
Asad Taherbhoy
Asad Taherbhoy
Angel Investor
Angel Star Ventures
Wei Tao
Wei Tao
Board Director & Chair, Bio/Genomics
Life Science Angels
Vince Wong
Vince Wong
CEO and President
BioCrossroads
Chris Yoo
Chris Yoo
General Partner and Managing Director
Xcellerant Ventures
Doug Zingale
Doug Zingale
Co-Founder & Managing Partner
Blue Goose Capital
Patrick-Cooke
Patrick Cooke, PhD
Associate
Merck Digital Sciences Studio
SERB Pharmaceuticals
Samuel Freedman
M&A Analyst
SERB Pharmaceuticals

Navigating CFIUS: Awareness and Opportunity for Biotech Startups in a Changing Investment Landscape

10 Jun

By Sougato Das, President and COO, LSN

Sougato-Das

CFIUS, short for the Committee on Foreign Investment in the United States, is an interagency committee tasked with reviewing foreign investments into U.S. companies that may present national security risks. Though created in 1975, CFIUS has recently expanded its focus to include sectors such as biotechnology, in light of evolving global priorities and concerns.

A recent presidential memorandum has signaled heightened attention to biotech transactions, particularly those involving sensitive technologies and personal health data. The memo also outlines a more streamlined process for investment reviews involving allies of the United States, while suggesting a more cautious stance toward investments from jurisdictions deemed non-aligned. Although not yet codified into law, these signals indicate that the regulatory environment is tightening for some international investors.

Biotech startups should not interpret this shift as a prohibition, but rather as an evolving framework that will increasingly require awareness, strategic planning, and legal clarity when engaging global investors and partners. This is particularly relevant for companies with potential funding interest from regions such as Asia, including China and, more recently, jurisdictions currently under enhanced CFIUS scrutiny.

Global Fundraising: A Numbers Game with Strategic Implications

For over a decade, Life Science Nation has been building and guiding early-stage companies through capital fundraising and licensing campaigns from a global perspective. There are two fundamental reasons why this work must be approached as a numbers game. In today’s fragmented global funding landscape, visibility, volume, and variety are essential for finding and securing the right partners. First, if you confine your outreach to your home region or country, you can quickly exhaust the pool of suitable targets. Second, when you do find a lead investor or licensing partner, they typically want to see a geographically diversified syndicate. As development progresses and commercialization strategies take shape, having informed and engaged partners across key global regions becomes not optional, but essential.

Failing to secure global relationships early on, whether due to limited strategy, policy restrictions, or lack of access, can create real obstacles to growth. Overly restrictive capital policies risk unintentionally slowing innovation and creating pressure for startups to move offshore. In an increasingly interconnected life science ecosystem, enabling global access to capital and partnerships is critical to maintaining U.S. leadership in biotech innovation.

Moving Forward

As the landscape for global biotech investment continues to evolve, early-stage startups will benefit from understanding CFIUS and related frameworks. While the regulatory terrain may shift, it still presents a significant opportunity for those who prepare strategically.

Early-stage biotech companies that navigate these cross-border dynamics with foresight and structure will be best positioned to engage international capital, generate high-value data, and build toward global commercialization.

Startups are encouraged to attend RESI Boston on June 16th or connect with industry experts for a deeper discussion. Register RESI Boston June now.